Financial Performance - The revenue for the six months ended June 30, 2022, was approximately RMB 944 million, an increase of 3.2% compared to RMB 915 million for the same period in 2021[7]. - The profit for the reporting period was approximately RMB 1 million, a turnaround from a loss of RMB 54 million in the same period of 2021[7]. - Revenue from medical beauty services was approximately RMB 878 million, a decrease of 1.6% from RMB 892 million in the previous year[20]. - Revenue from minimally invasive beauty services increased by approximately 24.4% to RMB 430 million, compared to RMB 345 million in the prior year[21]. - Revenue from cosmetic surgery services decreased by approximately 31.3% to RMB 62 million, down from RMB 91 million, primarily due to changes in consumer behavior influenced by the pandemic[21]. - The gross profit for the reporting period was approximately RMB 444 million, an increase of about 19.6% compared to RMB 371 million for the six months ended June 30, 2021[24]. - The gross profit margin was approximately 47.0%, up by about 6.5 percentage points from approximately 40.5% for the six months ended June 30, 2021, primarily due to high gross margins of 79.9% from newly launched medical beauty equipment[24]. - The total gross profit from medical beauty services was approximately RMB 392 million, an increase of about 9.8% from RMB 357 million for the six months ended June 30, 2021[26]. - The gross profit from minimally invasive beauty services was approximately RMB 192 million, a significant increase of about 32.2% from RMB 145 million for the six months ended June 30, 2021[26]. - Other income and gains for the reporting period were approximately RMB 24 million, an increase of about 50.0% from RMB 16 million for the six months ended June 30, 2021[28]. - The total administrative expenses for the reporting period were approximately RMB 186 million, an increase of about RMB 20 million compared to RMB 166 million for the six months ended June 30, 2021[28]. - The financial costs for the reporting period were approximately RMB 16 million, compared to RMB 11 million for the six months ended June 30, 2021[28]. - The net profit attributable to the owners of the parent company for the reporting period was approximately RMB 1 million, compared to a loss of RMB 54 million for the six months ended June 30, 2021[28]. Operational Developments - The company expanded its non-surgical medical beauty service capabilities by enhancing facilities and introducing new equipment over the past 12-18 months[8]. - The total operational area of medical beauty institutions increased from approximately 8,100 square meters before renovation to 14,100 square meters after renovation[9]. - The number of minimally invasive service rooms increased from 13 to 35 following the renovations of medical beauty institutions[9]. - The company plans to accelerate the development of various new medical beauty service patents to become the leading medical service technology team in the Yangtze River Delta region[11]. - The company is focusing on brand and product innovation driven by medical beauty technology and quality[8]. - The company has implemented strict control over sales, promotion, and marketing expenses, contributing to the profit turnaround[7]. - The company plans to establish a new medical beauty materials R&D and manufacturing platform in Suzhou, collaborating with well-known domestic universities[15]. - A new skincare product sales platform, "Ruiliang Skincare Collection Store," is set to launch, enhancing product sales channels and customer traffic[16]. - The company has initiated the construction of a new medical institution in Hainan, expecting to obtain relevant business licenses within the next 12 months[5]. Market Trends - The Chinese medical beauty market is projected to maintain double-digit growth, with a growth rate higher than other global markets[44]. - The consumer age group for medical beauty services in China primarily ranges from 21 to 40 years old, indicating a broad market base[44]. - The shift in consumer preference has moved from surgical services to non-surgical services like injection aesthetics and skin anti-aging, which are less invasive and have higher repurchase rates[45]. - The company is increasing investment in non-surgical medical beauty services to further develop international medical beauty brands[45]. - The overall external environment for the medical beauty industry remains stable, with increasing consumer acceptance and penetration rates[44]. - Regulatory measures in the medical beauty industry are being strengthened, promoting high-quality development and the elimination of non-compliant operators[44]. Shareholder Information - As of June 30, 2022, Mr. Fu Haishu holds 1,109,283,463 shares, representing 53.10% of the company's equity[48]. - The total number of shares issued by the company as of June 30, 2022, is 2,089,040,000[49]. - Major shareholders include Ruide Consulting Management Co., Ltd., holding 1,109,283,463 shares (53.10%), and Meitianxia Responsibility (Hong Kong) Co., Ltd., holding 129,128,745 shares (6.18%)[56]. - The company emphasizes good corporate governance principles to enhance shareholder value and ensure transparency and accountability[47]. - The company did not declare any interim dividends during the reporting period, consistent with the previous period where no dividends were declared[63]. - The board proposed amendments to the company's articles of association to comply with core shareholder protection standards, which were approved at the annual general meeting on June 10, 2022[65]. Financial Position - Cash and bank balances as of June 30, 2022, were approximately RMB 924 million, down from RMB 1,217 million as of December 31, 2021[28]. - As of June 30, 2022, the total liabilities of the group were approximately RMB 134.2 million, resulting in a debt-to-equity ratio of approximately 72.8%, down from 89.0% as of December 31, 2021[32]. - The total employee cost for the period was approximately RMB 30.2 million, accounting for about 32.0% of total revenue, a decrease from 40.8% for the same period in 2021[40]. - The group had a total of 382 employees as of June 30, 2022, a decrease from 395 employees as of December 31, 2021[36]. - The group has no significant contingent liabilities or guarantees as of June 30, 2022, consistent with the previous year[30]. - The group has no major investments or acquisitions planned as of June 30, 2022[35]. - The group plans to utilize approximately 71.0% of the net proceeds from its listing for expanding its medical beauty network, with a total of HKD 58.0 million allocated for this purpose[43]. - The group has allocated HKD 9.0 million for purchasing new medical beauty service equipment and treatment consumables, with all funds already utilized[43]. - The group has no significant interest rate risk as of the reporting date[33]. - The group is monitoring foreign exchange risks closely, particularly due to its holdings in HKD-denominated financial assets[34]. - The group has no major rate of exchange hedging policies in place but is considering prudent measures to mitigate related risks[34]. Cash Flow and Investments - The company reported a foreign exchange gain of RMB 1,522 thousand, contrasting with a loss of RMB 1,053 thousand in the previous year, indicating improved currency management[88]. - The company incurred RMB 8,557 thousand in capital expenditures for property, plant, and equipment, up from RMB 3,036 thousand in the previous year, representing an increase of approximately 182.5%[88]. - The net cash flow from financing activities was a net outflow of RMB 22,240 thousand, compared to a net inflow of RMB 7,926 thousand in the same period of 2021, indicating a significant change in financing strategy[88]. - The company received RMB 2,100 thousand in bank loans during the period, a decrease of 79% compared to RMB 10,000 thousand in the previous year[88]. - The company repaid RMB 20,100 thousand in bank loans, which is double the amount repaid in the same period last year (RMB 10,000 thousand)[88]. - The company reported a decrease in inventory and supplies from RMB 13,266,000 to RMB 9,024,000, indicating better inventory management[80]. - The company experienced a cash outflow from operating activities, with a net cash flow of RMB (393,000) compared to RMB (15,815,000) in the previous year, showing a significant reduction in cash burn[86]. - For the six months ended June 30, 2022, net cash flow from investing activities was RMB 29,522 thousand, a significant improvement from a net outflow of RMB 30,823 thousand in the same period of 2021[88]. Compliance and Governance - The company confirmed compliance with the standards set out in the code of conduct for securities transactions by directors during the reporting period[1]. - The company has not established any preferential rights for existing shareholders regarding the issuance of new shares[64]. - The accounting policies applied in preparing the interim financial information are consistent with those used in the previous annual financial statements, ensuring comparability[91]. - The audit committee reviewed and approved the interim financial results without any objections[67]. - There were no significant events occurring after the reporting period[136].

Financial Performance - Raily reported a significant increase in revenue, achieving a total of 1.2 billion RMB in 2021, representing a year-on-year growth of 25%[8] - For the year ended December 31, 2021, the company achieved total revenue of RMB 188.4 million, representing a year-on-year increase of 14.5%[23] - The company reported a net loss of RMB 18.3 million for the year, with a net loss attributable to shareholders of RMB 17.7 million[23] - The company experienced increased revenue but turned to a loss primarily due to stricter travel restrictions and significant currency exchange losses caused by the appreciation of the RMB[23] - The company recorded a loss of approximately RMB 18.3 million in 2021, compared to a profit of RMB 4.9 million in 2020[70] - The company reported a significant increase in foreign exchange losses, amounting to RMB 2,403,000, compared to RMB 256,000 in the previous year, marking an 838.7% increase[45] - The company achieved a total revenue of HKD 1.2 billion for the fiscal year, representing a year-over-year increase of 15%[113] - The company provided guidance for the next fiscal year, projecting revenue growth of 20% to $180 million[105] Customer Engagement and Services - The company expanded its service offerings, including aesthetic surgery, minimally invasive services, and skin beauty services, contributing to a 30% increase in customer visits[10] - Raily's customer retention rate has increased to 85%, attributed to enhanced service offerings and customer experience initiatives[10] - The number of active customers in 2021 was approximately 65,500, a decrease of 10.5% from 73,200 in 2020[34] - The average spending per customer increased to RMB 2,800 in 2021, up approximately 27.3% from RMB 2,200 in 2020[34] - The company aims to expand its minimally invasive beauty and skincare services to cater to the growing demand among young consumers[89] - The company is enhancing its marketing efforts through a combination of traditional outdoor advertising and online media marketing[31] Product Development and Innovation - The company began selling medical beauty equipment and products in 2021, focusing on surgical implants and skincare products, which is expected to drive future revenue growth[13] - The introduction of the initial true e-PTFE facial implants has improved product offerings, with a reported customer satisfaction rate of 90%[14] - The company plans to invest 100 million RMB in research and development for new aesthetic technologies over the next three years[8] - The company plans to establish a RAILY medical beauty materials R&D center in collaboration with medical schools or pharmaceutical companies[29] - New product launches are expected to contribute an additional $20 million in revenue, with a focus on innovative beauty technology[105] Market Expansion - The company aims to expand its market presence by opening two new clinics in Anhui province by the end of 2022, targeting a 20% increase in regional market share[8] - The company is expanding its market presence, targeting three new cities for service expansion in the upcoming year[105] - The company plans to expand its medical beauty service system through self-built or acquisition methods, focusing on standardized and scalable growth[28] Operational Efficiency - Raily's gross profit margin improved to 60% in 2021, up from 55% in the previous year, indicating better cost management and pricing strategies[9] - The gross profit margin for the year was 37.0%, with the dermatology segment achieving a gross profit margin of approximately 47.6%[23] - The overall gross margin for 2021 was approximately 37.0%, a decrease of about 11.7 percentage points compared to 2020, primarily due to reduced customer traffic and increased material and labor costs[68] - Cost management strategies are projected to improve operating margins by 5% in the next fiscal year[105] Employee and Management - The company has over 125 licensed physicians, with 71 having more than ten years of experience[24] - The company has a total of 395 employees as of the end of the year, an increase from 376 employees in the previous year, representing a growth of 5.1%[200] - The gender distribution among employees is 25% male (99 employees) and 75% female (296 employees), consistent with the previous year[200] - Employees receive regular health check-ups every two years and free non-material treatment and surgeries[200] - The company conducts exit interviews to understand the reasons for employee departures and gather feedback[200] Governance and Compliance - The board of directors emphasized the importance of sustainability initiatives in future business strategies[105] - The company has established a clear separation of roles between the chairman and the CEO, in compliance with governance codes[125] - The audit committee met twice this year to monitor the financial reporting process and compliance with laws and regulations[130] - The company has implemented necessary training for employees to ensure compliance with policies and procedures related to risk management and internal controls[138] Environmental, Social, and Governance (ESG) - The company emphasizes the importance of ESG governance for sustainable development and actively seeks stakeholder feedback to improve its ESG performance[156] - The company aims to reduce air pollutants, wastewater, and waste emissions by 5% by 2025 compared to 2021 levels[168] - The company has established policies related to environmental, social, and corporate governance, along with appropriate risk management measures[156] - The company has implemented various energy-saving measures, such as utilizing natural light and setting air conditioning temperatures to no lower than 26 degrees Celsius during summer[184] Financial Health - As of December 31, 2021, cash and bank balances were approximately RMB 121.7 million, down from RMB 158.9 million on December 31, 2020[70] - The total debt as of December 31, 2021, was approximately RMB 162.4 million, with a debt-to-equity ratio of about 89.0%[70] - The company has lease liabilities of approximately RMB 47.5 million as of December 31, 2021, compared to RMB 19.2 million on December 31, 2020[70]

Revenue and Growth - Revenue for the six months ended June 30, 2021, was approximately RMB 915 million, a significant increase of 55.8% compared to RMB 587 million for the same period in 2020[11]. - Revenue from medical beauty services was approximately RMB 892 million, representing a growth of about 55.2% from RMB 575 million in the previous year[25]. - Revenue from skin beauty services and minimally invasive beauty services increased by approximately 122.1% and 71.1%, reaching RMB 409 million and RMB 345 million respectively[27]. - For the six months ended June 30, 2021, total revenue from medical beauty services was RMB 89,194,000, and from consulting services was RMB 2,298,000, totaling RMB 91,492,000, representing an increase from RMB 58,730,000 in the same period of 2020[98]. - The total revenue for the period was approximately RMB 915 million, a significant increase of 55.8% compared to RMB 587 million for the same period in 2020[25]. Customer Metrics - Active customer count increased to 43,325, up 39.4% from 31,080 in the first half of 2020[12]. - Average spending per active customer rose to approximately RMB 2,059, an increase of about 11.4% from RMB 1,849 in the first half of 2020[12]. - New customer count reached 16,130, representing a growth of 15.8% compared to 13,928 in the first half of 2020[12]. - Repeat customer count increased to 27,195, a growth of 58.6% from 17,152 in the same period of 2020[12]. Financial Performance - The net loss for the period was approximately RMB 54 million, a reduction of about 53.8% from RMB 118 million in the same period of 2020[11]. - The gross profit for the period was approximately RMB 371 million, an increase of about 52.7% compared to RMB 243 million for the same period in 2020[30]. - The gross margin was approximately 40.5%, a decrease of about 0.9 percentage points from 41.4% in the previous year[30]. - The company recorded a loss of approximately RMB 5.4 million for the period, compared to a loss of RMB 11.8 million for the six months ended June 30, 2020[34]. - The company reported a pre-tax loss of RMB 5,549 thousand for the six months ended June 30, 2021, an improvement from a loss of RMB 12,352 thousand in the same period of 2020[90]. Expenses and Liabilities - The sales cost for the period was approximately RMB 544 million, an increase of about 57.9% from RMB 344 million in the previous year[28]. - Sales and distribution expenses were approximately RMB 25.2 million, an increase of about RMB 10.1 million from RMB 15.1 million for the six months ended June 30, 2020[34]. - Administrative expenses decreased to approximately RMB 16.6 million from RMB 20.3 million for the six months ended June 30, 2020, a reduction of about RMB 3.7 million[34]. - The total liabilities as of June 30, 2021, were approximately RMB 80.6 million, down from RMB 85.6 million as of December 31, 2020[38]. - The debt-to-equity ratio was 42.4% as of June 30, 2021, compared to 45.8% as of December 31, 2020[38]. Investments and Expansion - The company plans to complete an expansion of approximately 1,500 square meters at Wuhu Raily Medical Aesthetic Clinic, increasing total building area by about 106.8%[12]. - The company invested RMB 3.5 million to acquire a 25% stake in Bioris Medical (Beijing) Trading Co., Ltd. as part of its strategy to vertically expand its supply chain[12]. - The company is expanding its medical beauty facilities, increasing the total area from approximately 7,972 square meters to about 12,672 square meters, a growth of 59.0%[17]. - The company is implementing renovation and expansion plans for its medical beauty institutions to improve service capacity and customer experience[17]. - The company has committed to strategic acquisitions, allocating HKD 12.2 million (15.0%) of the net proceeds for this purpose by December 31, 2023[50]. Shareholder Information - As of June 30, 2021, Mr. Fu Haishu holds 1,109,283,463 shares, representing 53.10% of the company's equity[57]. - Major shareholder 瑞德咨询管理有限公司 holds 1,109,283,463 shares, representing 53.10% of the company's equity[62]. - The total number of shares issued by the company as of June 30, 2021, is 2,089,040,000 shares[64]. - The company did not declare any interim dividends for the six months ending June 30, 2020[64]. Compliance and Governance - The company has adopted the standard code of conduct for directors' securities transactions as per the listing rules[64]. - The company confirmed compliance with the standard code during the reporting period[64]. - The audit committee has reviewed and approved the interim financial information, ensuring compliance with relevant regulations and standards[76]. Cash Flow and Assets - The net cash used in operating activities for the six months ended June 30, 2021, was RMB (15,815) thousand, compared to RMB (9,238) thousand for the same period in 2020, indicating a worsening cash flow situation[90]. - Cash and cash equivalents at the end of the period were RMB 103,633,000, a significant increase from RMB 27,499,000 at the end of the previous year[92]. - The company’s cash and bank balances decreased from RMB 158,898 thousand as of December 31, 2020, to RMB 146,916 thousand as of June 30, 2021, a decline of about 7.5%[84]. - The company’s inventory increased from RMB 11,621 thousand as of December 31, 2020, to RMB 15,130 thousand as of June 30, 2021, representing an increase of approximately 29.0%[84]. - The total assets increased to RMB 140,935 thousand as of June 30, 2021, compared to RMB 137,651 thousand at the end of 2020[101].

Financial Performance - Raily Aesthetic Medicine reported a significant increase in revenue, achieving a total of 200 million RMB in 2020, representing a growth of 25% compared to the previous year[4]. - The company achieved total revenue of RMB 164.5 million for the year ended December 31, 2020, a decrease of 13.9% compared to the previous year[16]. - Net profit for the year was RMB 4.9 million, with a net profit attributable to shareholders of RMB 4.3 million, representing decreases of 52.2% and 57.0% respectively from 2019[16]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion in 2020, representing a growth of 15% compared to the previous year[70]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[70]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion in the last fiscal year, representing a 15% year-over-year growth[76]. - The company provided guidance for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion[76]. Market Expansion and Services - The company operates a network of four private medical aesthetic institutions, with three located in Zhejiang Province and one in Anhui Province, enhancing its market presence[4]. - Raily has expanded its service offerings to include dental aesthetic services, which enhances customer experience and promotes cross-selling opportunities[6]. - The company expanded its service offerings by establishing its fourth medical beauty institution in Wuhu, Anhui Province in July 2020[11]. - The company plans to expand its medical beauty institution network and is looking for acquisition opportunities in reputable medical beauty institutions to enhance market presence in Zhejiang Province[18]. - The company is expanding its market presence, planning to open 10 new clinics in key urban areas by the end of 2021[70]. - A strategic acquisition of a local competitor is anticipated to enhance market share and operational efficiency, expected to close by Q3 2021[70]. Customer Engagement and Retention - Raily aims to improve customer retention rates through comprehensive medical aesthetic services, including dental care and other auxiliary services[6]. - The total number of medical beauty customers in 2020 was 73,235, an increase of 4.9% from 69,835 in 2019, with new customers accounting for 43.5% of the total[24]. - The company aims to enhance customer engagement through digital platforms, targeting a 25% increase in online bookings[70]. - Customer complaints were minimal in 2020, with a high rate of repeat customers due to quality service and strict safety controls[189]. Operational Efficiency and Management - The company plans to optimize operational efficiency and enhance medical quality and safety management to increase market share in the medical beauty service industry[16]. - The company has started providing management consulting services to third-party medical aesthetic institutions since 2017, diversifying its business model[6]. - The company emphasizes improving quality, service, and efficiency in medical quality management and corporate social responsibility practices[21]. - The management team emphasized the importance of maintaining operational efficiency, targeting a 5% reduction in costs[76]. Safety and Compliance - Raily has implemented multiple safety protocols for equipment usage, ensuring compliance with national safety and efficacy standards[6]. - The company did not purchase medical liability insurance for its medical beauty institutions or medical staff in 2020, posing a risk to operations[31]. - The ongoing impact of COVID-19 has affected customer willingness to visit medical beauty institutions, impacting overall revenue[40]. - The group implemented various COVID-19 prevention measures, including providing disposable medical masks and disinfectants in office areas and additional protective gear in high-risk areas[150]. Corporate Governance - The board of directors consists of three executive directors, two non-executive directors, and three independent non-executive directors, ensuring a balanced composition for effective governance[80]. - The company has adhered to the corporate governance code since its listing date on December 28, 2020, confirming compliance with the relevant standards[80]. - The company has established a remuneration committee responsible for recommending compensation policies for directors and senior management[193]. - The independent non-executive directors have confirmed their independence according to the relevant listing rules[193]. Environmental, Social, and Governance (ESG) Initiatives - The company emphasizes the importance of ESG governance for sustainable development and has established clear responsibilities for the board to oversee ESG initiatives[113]. - The company aims to comply with national policies and regulations, ensuring timely and full tax payments as part of its stakeholder expectations[117]. - The company is committed to sustainability initiatives, aiming for a 50% reduction in waste by 2025[70]. - The company has set up appropriate communication channels for stakeholders to express their opinions and expectations, enhancing ESG performance[116]. Employee Management and Development - The company has 376 employees as of December 31, 2020, with 198 being medical professionals[16]. - Employee turnover rate was 42% for the entire workforce, with a higher turnover of 47% for employees under 30 years old[142][143]. - The group emphasizes employee development through a structured performance management system, linking performance evaluations to promotions and salary adjustments[151]. - The group provides various employee benefits, including social insurance and regular health check-ups every two years[140]. Financial Position and Investments - The company raised approximately HKD 81.7 million through its global offering on the Hong Kong Stock Exchange on December 28, 2020[16]. - The company has not utilized any proceeds from the IPO as of December 31, 2020[56]. - The company has approximately RMB 192 million in lease liabilities as of December 31, 2020, down from RMB 264 million in 2019[50]. - The company has established a comprehensive quality control system for medical beauty services, adhering to national standards and regulations to ensure safety and quality[161].